- Home
- DWTX vs POAI Comparison
DWTX vs POAI Comparison
Compare DWTX & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DWTX
- POAI
- Stock Information
- Founded
- DWTX 2012
- POAI 2002
- Country
- DWTX United States
- POAI United States
- Employees
- DWTX N/A
- POAI N/A
- Industry
- DWTX
- POAI Industrial Specialties
- Sector
- DWTX
- POAI Health Care
- Exchange
- DWTX NYSE
- POAI Nasdaq
- Market Cap
- DWTX 9.2M
- POAI 8.9M
- IPO Year
- DWTX N/A
- POAI N/A
- Fundamental
- Price
- DWTX $4.79
- POAI $0.80
- Analyst Decision
- DWTX Strong Buy
- POAI Hold
- Analyst Count
- DWTX 1
- POAI 1
- Target Price
- DWTX $10.00
- POAI N/A
- AVG Volume (30 Days)
- DWTX 27.2K
- POAI 177.4K
- Earning Date
- DWTX 08-14-2025
- POAI 08-12-2025
- Dividend Yield
- DWTX N/A
- POAI N/A
- EPS Growth
- DWTX N/A
- POAI N/A
- EPS
- DWTX N/A
- POAI N/A
- Revenue
- DWTX N/A
- POAI $1,729,269.00
- Revenue This Year
- DWTX N/A
- POAI $486.27
- Revenue Next Year
- DWTX N/A
- POAI $65.50
- P/E Ratio
- DWTX N/A
- POAI N/A
- Revenue Growth
- DWTX N/A
- POAI 24.17
- 52 Week Low
- DWTX $1.62
- POAI $0.55
- 52 Week High
- DWTX $29.28
- POAI $3.06
- Technical
- Relative Strength Index (RSI)
- DWTX N/A
- POAI 37.42
- Support Level
- DWTX N/A
- POAI $0.78
- Resistance Level
- DWTX N/A
- POAI $0.82
- Average True Range (ATR)
- DWTX 0.00
- POAI 0.05
- MACD
- DWTX 0.00
- POAI 0.00
- Stochastic Oscillator
- DWTX 0.00
- POAI 49.35
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.